SFPIA
LXRX icon

Stevens First Principles Investment Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-714
Closed -$12K – 220
2013
Q3 		$12K Sell
714
-286
-29% -$4.8K 0.01% 173
2013
Q2 		$15K Buy
+1,000
New +$15.2K 0.01% 171

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Stevens First Principles Investment Advisors's LXRX Position: Q4 2013 in Review

Stevens First Principles Investment Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2013, closing a stake of 714 shares — an estimated $12K sold.

Stevens First Principles Investment Advisors first reported a position in LXRX in Q2 2013 and held it in 2 quarters. The position peaked at $15K in Q2 2013. 109 funds tracked by Wall St. Rank hold LXRX as of Q4 2013.

  • Stevens First Principles Investment Advisors reported no remaining Lexicon Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 714 Lexicon Pharmaceuticals shares in Q4 2013, an estimated $12K.
  • Stevens First Principles Investment Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Stevens First Principles Investment Advisors's Lexicon Pharmaceuticals position peaked at $15K in Q2 2013.
  • 109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2013.

Based on Stevens First Principles Investment Advisors's 13F filing for Q4 2013, filed 7 Feb 2014.